Design Therapeutics, Inc. is a pharmaceutical company based in the United States. With an ESG risk rating score of 28.3, the company is categorized as posing a medium level of risk. Specializing in the development of GeneTACTM molecules, a unique class of small-molecule gene-targeted chimera therapies, Design Therapeutics focuses on addressing the underlying causes of diseases resulting from inherited nucleotide repeat expansion mutations. Their product candidates include treatments for Friedreich ataxia, Fuchs endothelial corneal dystrophy, and other serious monogenic diseases.